Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Ispinesib · SB-715992

Small molecule · Inhibitor of kinesin spindle protein (KSP) (KIF11) · developed by GlaxoSmithKline

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Ispinesib?

Ispinesib is a synthetic small molecule that selectively inhibits kinesin spindle protein (KSP), blocking mitotic spindle assembly and inducing cell cycle arrest and death in dividing tumor cells. It is studied in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SB-715992
Drug type
Small molecule
Targets
kinesin spindle protein (KSP) (KIF11)
Mechanism
Inhibitor of kinesin spindle protein (KSP) (KIF11)
Pathways
mitotic spindle assembly, cell cycle arrest
Therapy area
Oncology
Developer
GlaxoSmithKline
In trials of
CYTK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
BKT5F9C2NI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00607841 Phase 1 Breast Neoplasms Terminated CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast Neoplasms

Other drugs acting on KIF11

SB-743921 Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.